Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i Sep 25 | 2023FDA Approves Jardiance for Adults with CKD; Abbott Completes Bigfoot Acquisition; Insulet Publishes “Market Opportunity & Impact of GLP-1s” Presentation; Lilly initiates Ph3 H2H Orforglipron vs. Semaglutide and New Ph3b Tirzepatide Max Dose Study in ObesityPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Sep 21 | 2023ITCA 650 Negative Adcom Vote; Medtronic Receives CE Mark for Simplera; 89bio’s Pegozafermin in NASH Receives Breakthrough Therapy Designation; Dexcom Canada Partners with RxFood for Diabetes Management; Novo Nordisk Foundation to Establish New Cell Therapy FacilityPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Sep 21 | 2023Ypsomed Signs Long-Term Autoinjector Supply Deal with Novo; Lilly Files Lawsuits Over Copycat Mounjaro ProductsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Sep 19 | 2023ITCA 650 Faces Uphill Battle as FDA Releases Adcom Briefing Docs; Novo Receives Form 483 Observations; Abbott and WeightWatchers Launch Connected App ExperiencePurchase Blast
$599
Posted in: Dual/triple agonist, Insulin Delivery, Other Sep 18 | 2023Novo Hires Private Contract Manufacturer for Wegovy Assembly and Packaging; Roche's Tubeless Patch Pump System Receives 510(k) Clearance; Beta Bionics Introduces iLet Bionic Pancreas; NeuroBo Doses First Patient for Ph2a DA-1241 Study in NASHPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other Sep 14 | 2023Lilly Initiates New Ph2 Study Investigating High Doses of Tirzepatide in Patients with T2DM and Obesity; Gan & Lee Doses First Patient in Ph2 QW Insulin Study; BMS discontinues NASH assetPurchase Blast
$599
Posted in: Glucose Monitoring, Other Sep 13 | 2023Madrigal Receives Priority Review for Resmetirom NASH NDA; Adipo Therapeutics Appoints Keith Johns as CSO; Novo Nordisk Conducts a Two-for-One Stock Split; Nemaura Announces Interim Miboko Study ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Sep 12 | 2023Entera Bio to Collaborate with OPKO Biologics for Obesity; Dexcom Launches Dexcom ONE in France; Altimmune Completes Ph2 Obesity Trial Dosing; Vertex Acquires Novel GPCR-targeted ProgramPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i Sep 11 | 2023September CHMP Agenda; Nemaura Announces Interim 24-Hour Wear sugarBEAT Results; Madrigal Appoints Bill Sibold as CEOPurchase Blast
$599
Posted in: Other Sep 07 | 2023Roche and Alnylam Report Topline Ph2 Hypertension Results; ITBMed Initiates Ph2 Siplizumab Study in New Onset T1DM PatientsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Sep 06 | 2023FENIX Analysis: Thoughts on the Abbott/Bigfoot Acquisition - A New Era for the CGM and Insulin Delivery Market?Purchase Blast
$599
Posted in: Dual/triple agonist, Other Sep 06 | 2023Novo Partners with Broad Institute of MIT and Harvard for T2DM; Viking Initiates Ph2 Dual Agonist Obesity Trial; Cytokinetics Initiates Ph3 Aficamten Trial in Non-Obstructive HCMPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Sep 05 | 2023Abbott to Acquire Bigfoot; Novo Launches Wegovy in UK; Sernova and Glyscend Appoint New CEOs; SomaLogic Expands Agreement with Novo Through 2025; Novo’s Biocorp Acquisition Updates; Diamyd to Initiate Ph3 DIAGNODE-3 in USPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Sep 01 | 2023Beta Bionics Secures $100M in Series D Funding; Senators Ask for Clarity on Lilly, Novo, and Sanofi’s Low-cost Insulin ProductsPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Other Aug 31 | 2023The ITCA 650 Story Lives on; i2o Therapeutics Appoints Kurt Graves as CEO; Biomea Appoints Juan Pablo Frias as CMOPurchase Blast
$599
Posted in: GLP-1RA, Other Aug 30 | 2023Novo to Acquire Another Obesity Company; Zealand Receives Priority Review for Dasiglucagon CHI NDAPurchase Blast
$599
Posted in: ESPR, Glucose Monitoring, Insulin Delivery, Other Aug 28 | 2023Novartis Presents Long-Term Leqvio Data; Insulet Launches Omnipod 5 in Germany; Esperion Presents Additional CLEAR Outcomes Results; Amgen Presents Olpasiran Ph2 OCEAN(a)-DOSE Extension ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, SGLT2i Aug 25 | 2023Novo and Lilly Win Again with Positive STEP HFpEF Full ResultsPurchase Blast